Immunosuppressive Regulatory Cells in Cancer Immunotherapy: Restrain or Modulate?

Overview

Journal Hum Cell

Publisher Springer

Specialty Cell Biology

Date 2024 May 30

PMID 38814516

Authors

Yan Wu

Dongfeng Chen

Yang Gao

Qinggang Xu

Yang Zhou

Zhong Ni

Manli Na

Affiliations

Soon will be listed here.

Abstract

Immunosuppressive regulatory cells (IRCs) play important roles in negatively regulating immune response, and are mainly divided into myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs). Large numbers of preclinical and clinical studies have shown that inhibition or reduction of IRCs could effectively elevate antitumor immune responses. However, several studies also reported that excessive inhibition of IRCs function is one of the main reasons causing the side effects of cancer immunotherapy. Therefore, the reasonable regulation of IRCs is crucial for improving the safety and efficiency of cancer immunotherapy. In this review, we summarised the recent research advances in the cancer immunotherapy by regulating the proportion of IRCs, and discussed the roles of IRCs in regulating tumour immune evasion and drug resistance to immunotherapies. Furthermore, we also discussed how to balance the potential opportunities and challenges of using IRCs to improve the safety of cancer immunotherapies.

References

Pinti M, Appay V, Campisi J, Frasca D, Fulop T, Sauce D . Aging of the immune system: Focus on inflammation and vaccination. Eur J Immunol. 2016; 46(10):2286-2301. PMC: 5156481. DOI: 10.1002/eji.201546178. View

Netea M, Schlitzer A, Placek K, Joosten L, Schultze J . Innate and Adaptive Immune Memory: an Evolutionary Continuum in the Host's Response to Pathogens. Cell Host Microbe. 2019; 25(1):13-26. DOI: 10.1016/j.chom.2018.12.006. View

Bruger A, Dorhoi A, Esendagli G, Barczyk-Kahlert K, van der Bruggen P, Lipoldova M . How to measure the immunosuppressive activity of MDSC: assays, problems and potential solutions. Cancer Immunol Immunother. 2018; 68(4):631-644. PMC: 11028070. DOI: 10.1007/s00262-018-2170-8. View

Tanaka A, Sakaguchi S . Regulatory T cells in cancer immunotherapy. Cell Res. 2016; 27(1):109-118. PMC: 5223231. DOI: 10.1038/cr.2016.151. View

Li F, Zhao Y, Wei L, Li S, Liu J . Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer. Cancer Biol Ther. 2018; 19(8):695-705. PMC: 6067871. DOI: 10.1080/15384047.2018.1450116. View

Fultang L, Panetti S, Ng M, Collins P, Graef S, Rizkalla N . MDSC targeting with Gemtuzumab ozogamicin restores T cell immunity and immunotherapy against cancers. EBioMedicine. 2019; 47:235-246. PMC: 6796554. DOI: 10.1016/j.ebiom.2019.08.025. View

Pang B, Zhen Y, Hu C, Ma Z, Lin S, Yi H . Myeloid-derived suppressor cells shift Th17/Treg ratio and promote systemic lupus erythematosus progression through arginase-1/miR-322-5p/TGF-β pathway. Clin Sci (Lond). 2020; 134(16):2209-2222. DOI: 10.1042/CS20200799. View

Chen X, Baumel M, Mannel D, Howard O, Oppenheim J . Interaction of TNF with TNF receptor type 2 promotes expansion and function of mouse CD4+CD25+ T regulatory cells. J Immunol. 2007; 179(1):154-61. DOI: 10.4049/jimmunol.179.1.154. View

Gneo L, Rizkalla N, Hejmadi R, Mussai F, De Santo C, Middleton G . TGF-β orchestrates the phenotype and function of monocytic myeloid-derived suppressor cells in colorectal cancer. Cancer Immunol Immunother. 2021; 71(7):1583-1596. PMC: 9188538. DOI: 10.1007/s00262-021-03081-5. View

10.

King R, Shukla S, He C, Vernucci E, Thakur R, Attri K . CD73 induces GM-CSF/MDSC-mediated suppression of T cells to accelerate pancreatic cancer pathogenesis. Oncogene. 2022; 41(7):971-982. PMC: 8840971. DOI: 10.1038/s41388-021-02132-6. View

11.

Li Y, Yang B, Miao H, Liu L, Wang Z, Jiang C . Nicotinamide N -methyltransferase promotes M2 macrophage polarization by IL6 and MDSC conversion by GM-CSF in gallbladder carcinoma. Hepatology. 2023; 78(5):1352-1367. DOI: 10.1097/HEP.0000000000000028. View

12.

Tcyganov E, Mastio J, Chen E, Gabrilovich D . Plasticity of myeloid-derived suppressor cells in cancer. Curr Opin Immunol. 2018; 51:76-82. PMC: 5943174. DOI: 10.1016/j.coi.2018.03.009. View

13.

Marguier A, Laheurte C, Lecoester B, Malfroy M, Boullerot L, Renaudin A . TIE-2 Signaling Activation by Angiopoietin 2 On Myeloid-Derived Suppressor Cells Promotes Melanoma-Specific T-cell Inhibition. Front Immunol. 2022; 13:932298. PMC: 9353943. DOI: 10.3389/fimmu.2022.932298. View

14.

Turrini R, Pabois A, Xenarios I, Coukos G, Delaloye J, Doucey M . TIE-2 expressing monocytes in human cancers. Oncoimmunology. 2017; 6(4):e1303585. PMC: 5414874. DOI: 10.1080/2162402X.2017.1303585. View

15.

Innamarato P, Pilon-Thomas S . Reactive myelopoiesis and the onset of myeloid-mediated immune suppression: Implications for adoptive cell therapy. Cell Immunol. 2021; 361:104277. PMC: 7901256. DOI: 10.1016/j.cellimm.2020.104277. View

16.

Xu Y, Yan J, Tao Y, Qian X, Zhang C, Yin L . Pituitary hormone α-MSH promotes tumor-induced myelopoiesis and immunosuppression. Science. 2022; 377(6610):1085-1091. DOI: 10.1126/science.abj2674. View

17.

Bah I, Kumbhare A, Nguyen L, McCall C, El Gazzar M . IL-10 induces an immune repressor pathway in sepsis by promoting S100A9 nuclear localization and MDSC development. Cell Immunol. 2018; 332:32-38. PMC: 6129403. DOI: 10.1016/j.cellimm.2018.07.003. View

18.

Bode J, Albrecht U, Haussinger D, Heinrich P, Schaper F . Hepatic acute phase proteins--regulation by IL-6- and IL-1-type cytokines involving STAT3 and its crosstalk with NF-κB-dependent signaling. Eur J Cell Biol. 2011; 91(6-7):496-505. DOI: 10.1016/j.ejcb.2011.09.008. View

19.

Cheung E, Vousden K . The role of ROS in tumour development and progression. Nat Rev Cancer. 2022; 22(5):280-297. DOI: 10.1038/s41568-021-00435-0. View

20.

Lv Y, Zhang B, Zhai C, Qiu J, Zhang Y, Yao W . PFKFB3-mediated glycolysis is involved in reactive astrocyte proliferation after oxygen-glucose deprivation/reperfusion and is regulated by Cdh1. Neurochem Int. 2015; 91:26-33. DOI: 10.1016/j.neuint.2015.10.006. View